MX2019012807A - Uso de compuestos de tiol para tratar enfermedades neurológicas. - Google Patents

Uso de compuestos de tiol para tratar enfermedades neurológicas.

Info

Publication number
MX2019012807A
MX2019012807A MX2019012807A MX2019012807A MX2019012807A MX 2019012807 A MX2019012807 A MX 2019012807A MX 2019012807 A MX2019012807 A MX 2019012807A MX 2019012807 A MX2019012807 A MX 2019012807A MX 2019012807 A MX2019012807 A MX 2019012807A
Authority
MX
Mexico
Prior art keywords
neurological disease
thiol compounds
treat neurological
thiols
brain
Prior art date
Application number
MX2019012807A
Other languages
English (en)
Inventor
Sara Louise Isbell
Todd Zankel
Original Assignee
Mercaptor Discoveries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mercaptor Discoveries Inc filed Critical Mercaptor Discoveries Inc
Publication of MX2019012807A publication Critical patent/MX2019012807A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente divulgación se refiere, en general, al uso de tioles difusibles pequeños en el tratamiento de enfermedades neurodegenerativas asociadas con la excitotocidad del glutamato, la agregación de proteínas y el estrés oxidativo en el sistema nervioso central, particularmente en el cerebro.
MX2019012807A 2017-04-24 2018-04-24 Uso de compuestos de tiol para tratar enfermedades neurológicas. MX2019012807A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762489132P 2017-04-24 2017-04-24
PCT/US2018/029145 WO2018200527A1 (en) 2017-04-24 2018-04-24 Use of thiol compounds to treat neurological disease

Publications (1)

Publication Number Publication Date
MX2019012807A true MX2019012807A (es) 2020-07-14

Family

ID=62165640

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012807A MX2019012807A (es) 2017-04-24 2018-04-24 Uso de compuestos de tiol para tratar enfermedades neurológicas.

Country Status (8)

Country Link
US (4) US20190029977A1 (es)
EP (1) EP3615013B1 (es)
KR (1) KR20200007836A (es)
CN (1) CN110996929A (es)
AU (1) AU2018258284A1 (es)
CA (1) CA3097510A1 (es)
MX (1) MX2019012807A (es)
WO (1) WO2018200527A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3602046A1 (en) * 2017-03-28 2020-02-05 Janssen Vaccines & Prevention B.V. Methods for detection of tau protein aggregation modulating compounds
AU2018258284A1 (en) 2017-04-24 2019-12-19 Mercaptor Discoveries, Inc. Use of thiol compounds to treat neurological disease
WO2019210035A1 (en) * 2018-04-25 2019-10-31 Horizon Orphan Llc Methods of treating excitotoxicity disorders
US20240247001A1 (en) 2022-12-16 2024-07-25 Astrazeneca Ab 2,6,9-trisubstituted purines
WO2026004978A1 (ja) * 2024-06-27 2026-01-02 学校法人関西医科大学 神経変性疾患又はせん妄の予防又は治療剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4021139A1 (de) * 1990-07-03 1992-01-09 Kuebler Gmbh Dr Verfahren und pharmazeutische mischung zur erhaltung von zellwachstum und zellteilung mittels thiolen
US5554655A (en) 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
WO2004006900A2 (en) 2002-07-11 2004-01-22 Immune Network Ltd. Sulphydryl compounds in combination with sulphone or sulphnamide conpounds for use in microbial inflammatory diseases
US20100222421A1 (en) 2009-02-27 2010-09-02 National Defense Medical Center Usage of Baicalein in the Preparation of a Pharmaceutical Composition for the Treatment of Traumatic Brain Injury
EP2906596B1 (en) 2012-10-12 2023-12-27 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
EP2935627A4 (en) 2012-12-21 2016-09-28 Univ Columbia BIOMARKER FOR CHRONIC TRAUMATIC ENZEPHALOPATHY
EP3316877B1 (en) * 2015-07-02 2019-10-30 Horizon Orphan LLC Ado-resistant cysteamine analogs and uses thereof
AU2018258284A1 (en) 2017-04-24 2019-12-19 Mercaptor Discoveries, Inc. Use of thiol compounds to treat neurological disease

Also Published As

Publication number Publication date
US20190029977A1 (en) 2019-01-31
EP3615013A1 (en) 2020-03-04
US20210069129A1 (en) 2021-03-11
CA3097510A1 (en) 2018-11-01
US12128014B2 (en) 2024-10-29
CN110996929A (zh) 2020-04-10
AU2018258284A1 (en) 2019-12-19
EP3615013B1 (en) 2024-08-14
US20250177330A1 (en) 2025-06-05
KR20200007836A (ko) 2020-01-22
EP3615013C0 (en) 2024-08-14
NZ759537A (en) 2025-10-31
US20230115413A1 (en) 2023-04-13
WO2018200527A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
MX2019012807A (es) Uso de compuestos de tiol para tratar enfermedades neurológicas.
ZA202004764B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
EP4421094A3 (en) Targeted therapeutic agents and uses thereof
IL287032A (en) Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
TW201613964A (en) Improved A[beta] protofibril binding antibodies
PH12016500840A1 (en) Methods of using interleukin-10 for treating diseases and disorders
MY169165A (en) Anti-pdgfr-beta antibodies and uses thereof
EP3688021A4 (en) Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
MX2015010749A (es) Anticuerpos humanos para nav1.7.
CU20160151A7 (es) 2-AMIN0-6-METI L-4,4a, 5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EP4406536A3 (en) Cystathionine beta-synthase enzyme for treatment of homocystinuria
EP3845565A3 (en) Antibodies against bace1 and use thereof for neural disease immunotherapy
WO2015197193A3 (en) New use for jnk inhibitor molecules for treatment of various diseases
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
MX2021005346A (es) Constructos de suministro para transcitosis y metodos relacionados.
EP4570317A3 (en) Compounds for the treatment of bovine or swine respiratory disease
EA201691567A1 (ru) Способы лечения легких травм головного мозга
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
WO2018154118A3 (en) Aromatic compounds which enhance notch signaling, for use in therapy
WO2020039088A3 (en) Aromatic molecules for use in the treatment of pathological conditions
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
PH12021551419A1 (en) New conjugated nucleic acid molecules and their uses
MX2021006865A (es) Anticuerpos anti-alfa-sinucleina y usos de estos.